Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Nov 5, 2024
Deals
Novo to use Ascendis’ TransCon for once-monthly GLP-1R agonist
Deals report: AbbVie-EvolveImmune, Genmab-Revitope and GSK-Chimagen partner for T cell engagers
BioCentury | May 31, 2024
Product Development
Immunotherapies break into cold colorectal cancers at ASCO
Data from Regeneron, Agenus and others highlight immuno-oncology progress in genetically stable colorectal cancer
BioCentury | Apr 17, 2024
Product Development
Cullinan adds T cell engagers to modality migration from cancer to autoimmunity
Cullinan raises a $280 million PIPE to develop CLN-978 for lupus
BioCentury | Dec 23, 2023
Discovery & Translation
Taking next-gen mAbs to new heights will lead modality innovation
Execs and investors weigh in on which technologies will yield the biggest gains in innovation in the near term and beyond: BioCentury survey
BioCentury | Dec 19, 2023
Product Development
Genentech positions bispecifics as durable options via ASH data
Fixed-duration doses of Lunsumio, Columvi led to responses that persisted long after treatment was stopped
BioCentury | Dec 14, 2023
Deals
Dec. 13 Quick Takes: Vertex heads off patent issues with Editas deal
Plus: Pfizer loses $11B in value after 2024 guidance and updates from J&J, Shattuck Labs, Vir, CARsgen, Freya and EvolveImmune
BioCentury | Nov 10, 2023
Product Development
Costimulatory bispecifics bring new biology to T cell engagers
Abstracts at SICT, ASH describe T cell engagers targeting alternative receptors on the immune cells
BioCentury | Mar 2, 2023
Emerging Company Profile
Cargo carrying pivotal-ready CD22 CAR with $200M A round
Behind the lead asset are other technologies from co-founder Crystal Mackall to overcome common mechanisms of cancer drug resistance
BioCentury | Nov 1, 2019
Emerging Company Profile
Tmunity: Manufacturing momentum for CAR and TCR therapies
How Tmunity’s focus on CMC for its engineered T cell therapies factored into its $75M series B
Items per page:
1 - 10 of 111